1.Kupfermann I. Learning and Memory, Principles of neural science. London: Prentice Hall International; 1993.p.997-1008.
2.Franchis P, Palmer A, Snape M, Wilcock G. The cholinergic hypothesis of Alzheimers disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66; 137-147.
3.Beers MH. The Merck manual of medical information, 2nded. Home ed.New Jersey: Merck and Co, INC; 2003.p.479.
4.Parle M, Dhingra D, Kulkarni SK. Neurochemical basis of learning and memory. Indian J Pharm Sci 2004; 66; 371-376.
5.Giurgea CE. The nootropic concept and its prospective implications. Drug Dev Res 1982; 2:441-446.
6.Croisile B, Trillet M, Fondarai J, Laurent B, Mauguierf F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993; 43;301-305.
7.Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 2002; 13:217-224.
8.Moyersoons F, Giurgea CE. Protective effect of piracetam in experimental barbiturate intoxication: EEG and behavioural studies. Arch I Pharmacodyn 1974; 210:38-48.
9.Altas E, Ucuncu H, Aktan B, Selimoglu E. The combined effect of piracetam in preventing cisplatin induced ototoxicity in a guinea pig model and gentamicin. Pain Clinic 2004; 16; 427-435.
10.Deviatkina TA, Vazhnichaia EM, Lytsenko RV. Characteristics of lipid peroxidation in various tissues during acute stress and its correction by piracetam and cerebrolysin. Exp Clin Pharmacol 2000; 63:38-41.
11.Bul’on VV, Zavodskaia IS, Khnychenko LK. The effect of neurotropic agents on lipid peroxidation in the heart and stomach with neurogenic lesions. Exp Clin Pharmacol 1994; 57:18-20.
12.Marini H, Costa C, Passaniti M, Esposito M, Campo GM, Ientile R, et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sci 2004; 74:1253-1264.
13.Zargari A. Medicinal Plants. Tehran: Tehran University Press; Vol. III, 1989.
14.Reddy DS. Assessment of nootropic and amnesic activity of centrally acting agents. Indian J Pharmacol 1997; 29: 208-221.
15.Kulkarni SK. Handbook of experimental pharmacology. 3rd ed.Delhi: Vallabh Prakashan; 2005.
16.Vyawahare NS, Nikam AP, Sharma RG, Deshpande MM, Tarnalli AD, Bodhankar SL. Effect of Clitoria ternatea extract on radial arm maze task performance and central cholinergic activity in rats. J Cell Tissue Res 2007; 7:949-952.
17.Vyawahare NS, Bodhankar SL. Effect of Argyreia speciosa extract on learning and memory paradigms in mice. Pharmacognosy Magazine 2009; 17:43-48.
18.Pourmotabbed A, Tahmasian M, 1Shahi M, Karami Darabkhani H, Fathollahi Y. Facilitating effects of morphine dependence on spatial learning and memory in rat. Daru 2007; 15:156-161.
19.Kikusui T, Tonohiro T,Kaneko T. Simultaneous evaluation of spatial working memory and motivation by the allocentric place discrimination task in the water maze in rats. J Vet Med Sci 1999; 61:673-681.
20.Trease GE, Evans WC. Pharmacognosy. London: Bailliere Tindall Press; 1983.
21.Kesari AN, Gupta RK, Singh SK, Diwakar S, Watal G. Hypoglycemic and antihyperglycemic activity of Aegle marmelos seed extract in normal and diabetic rats. J Ethnopharmacol 2006; 107; 374-379.
22.Andreoli TE, Carpenter CCJ, Bennett JC, Plum F. Cecil Essentials of Medicine.4thed. Philadelphia: Saunders WB Co; 2002.
23.Thakur VD, Mengi SA. Neuropharmacological profile of Eclipta alba (Linn.) Hassk. J Ethnopharmacol 2005; 102:23-31.
24.Kulkarni SK. Hand book of experimental Pharmacology. 3rd ed. New Delhi: Vallabh Prakashan; 2005.
25.Achliya G, Barhate U, Wadokar S, Dorle A. Effect of brahmi ghrita, a polyherbal formulation on learning and memory paradigms in experimental animals. Indian J Pharmacol 2004; 03:159-162.
26.Vogel HG,Vogel WH. Drug discovery and evaluation: Pharmacological assay. Heidelberg: Springer- Verlag Berlin; Vol.II, 2002.
27.Vyawahare NS, Bodhankar SL. Neuropharmacological profile of Piper betel leaves extract in mice. Pharmacologyonline 2007; 2:146-162.
28.Jain NN, Ohal CC, Shroff SK, Bhutada RH, Somani RS, Kasture VS, et al. Clitoria ternatea and CNS. Pharmacol Biochem Behav 2002; 75:529-536.
29.Tripathi Y, Chaurasia S, Tripathi E. Bacopa monniera Linn as anantioxidant: mechanism of action. Indian J Exp Biol 1996; 34:523-526.
30.Lee SC, Moon YS, You KH. Effects of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol treated rats in passive avoidance performance. J Ethanopharmacol 2000; 69: 01-08.
31.Ni JM, Ohta H, Matsumoto K, Watanabe H. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res 1994; 653:231-236.
32.Sarti C, Pantoni L, Bartolini L, Inzitari D. Cognitive impairment and chronic cerebral hypoperfusion: What can be learned from experimental models. J Neurol Sci 2002; 203/204:263-266.
33.Gabryel B, Adamek M, Pudelko A, Malecki A, Trzeciak HI. Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23:19¬31.
34.Moriau M, Crasborn L, Lavenne-Pardonge E, Von Frenckell R. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung 1993; 43:110-118.
35.Moran TH, Capone GT, Knipp S, Davisson MT, Reeves RH, Gearhart JD. The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol Behav 2002; 77:403-409.
36.Nomura T, Nishizaki T. Nefiracetam facilitates hippocampal neurotransmission by a mechanism independent of the piracetam and aniracetam action. Brain Res 2000; 870:157-162.